WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201931

CAS#: 1028486-01-2

Description: Alisertib, also known as MLN8237, is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.

Chemical Structure

CAS# 1028486-01-2

Theoretical Analysis

MedKoo Cat#: 201931
Name: Alisertib
CAS#: 1028486-01-2
Chemical Formula: C27H20ClFN4O4
Exact Mass: 518.11571
Molecular Weight: 518.9
Elemental Analysis: C, 62.49; H, 3.88; Cl, 6.83; F, 3.66; N, 10.80; O, 12.33

Size Price Shipping out time Quantity
25mg USD 150 Same Day
50mg USD 250 Same Day
100mg USD 450 Same Day
200mg USD 750 2 Weeks
500mg USD 1550 2 Weeks
1g USD 2850 2 Weeks
2g USD 5050 2 Weeks
5g USD 7650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-08. Prices are subject to change without notice.

Alisertib, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 1028486-06-7 (sodium anhydrous)   1208255-63-3 (sodium)  

Synonym: MLN8237; MLN-8237; MLN 8237; alisertib.

IUPAC/Chemical Name: 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid


InChi Code: InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)


Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Soluble in DMSO, not in water 100.0

Preparing Stock Solutions

The following data is based on the product molecular weight 518.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Preparation of [(phenylpyrimidobenzazepinyl)amino]methoxybenzoic acid derivatives for us as antitumor agents. Claiborne, Christopher F.; Sells, Todd B.; Stroud, Stephen G. (Millennium Pharmaceuticals, Inc., USA). PCT Int. Appl. (2008), 43pp. CODEN: PIXXD2 WO 2008063525 A1 20080529 . Patent written in English. Application: WO 2007-US23948 20071114. Priority: US 2006-859340 20061116. 

Additional Information

MLN-8237 is an Aurora A kinase blocker designed to disrupt the cycle of cancer cells. It is being tested in several types of cancer as monotherapy and in combination with different chemotherapy regimens. Millennium expects MLN-8237 to progress to mid-stage trials later in 2009. If MLN-8237 survives the clinical trial process, it may become the first approved therapy in the Aurora A kinase blocker class. Millennium is in a race, however, with research and development divisions at other pharmaceutical companies that are testing their own Aurora A kinase blockers. see: .
  Current developer:   Millennium Pharmaceuticals, Inc.